The IDO+SI in stage III breast cancer was significantly higher than those in stage II or stage I breast cancer, which were 22.47 ± 10.79%, 11.72 ± 6.48%, and 8.95 ± 3.79%, respectively (P < 0.05). This evidence concerns the gene IDO1 and breast cancer.